MỘT SỐ CHỈ SỐ TẾ BÀO MÁU NGOẠI VI Ở BỆNH NHÂN ĐỒNG MẮC UNG THƯ TẠNG VÀ BỆNH MÁU ÁC TÍNH

Abstract

Objectives: Describe some peripheral blood cell indices in patients with co-occuring solid tumor and hematologic malignancies at the National Institute of Hematology and Blood Transfusion in 2020-2023. Methods and materials: Observation, retrospective, 63 patients were diagnosed with co-occuring solid tumor and hematologic malignancies cancer at the National Institute of Hematology and Blood Transfusion in 2020-2023. Results: At the time of analysis, 63 patients were identified with concomitant solid tumors and hematologic malignancies, with a median age of 50 years. Among solid tumors, thyroid carcinoma was the most frequently observed (27%). Acute leukemia accounted for the majority (63.5%) of hematologic malignancies. The median interval between the diagnoses of the two malignancies was 42 months. Hematologic abnormalities affecting at least one cell lineage were present in 95.2% of cases, with pancytopenia noted in 55.6%. Leukocyte abnormalities were most prevalent (84.1%), with a trend toward leukocytosis (median white blood cell count: 17 G/l); leukopenia was observed in only 19% of patients. Anemia was found in 77.8% of patients, predominantly normochromic (68.3%). Platelet abnormalities were observed in 74.6%, with thrombocytopenia in 57.2% and thrombocytosis in 17.4% of cases. Conclusion: In patients diagnosed with solid tumors, the emergence of hematologic abnormalities—particularly persistent leukocytosis unrelated to infection, or significant deviations in platelet counts (either thrombocytopenia or thrombocytosis)—should raise clinical suspicion and warrant evaluation for potential coexisting hematologic malignancies.